Investor TCG Crossover GP II, LLC
13D/G Filings

This page shows a list of all the recent 13D/G filings made by TCG Crossover GP II, LLC . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2025-08-14 13G/A 1,933,333
2025-05-15 13G/A 1,871,482
2025-05-15 13G/A DNTH / Dianthus Therapeutics, Inc. 1,501,624 1,501,624
2025-01-03 13G RAPT / RAPT Therapeutics, Inc. 13,193,110
2024-12-03 13G CDTX / Cidara Therapeutics, Inc. 1,005,901
2024-11-22 13G DNTH / Dianthus Therapeutics, Inc. 1,501,624
2024-11-20 13G TNGX / Tango Therapeutics, Inc. 10,500,612
2024-11-13 13G/A MLYS / Mineralys Therapeutics, Inc. 3,185,185 2,470,265
2024-11-13 13G/A ATXS / Astria Therapeutics, Inc. 4,368,928 2,761,861
2024-11-07 13G EYPT / EyePoint Pharmaceuticals, Inc. 3,572,335
2024-09-27 13G THRD / Third Harmonic Bio, Inc. 2,415,000
2024-09-20 13G FULC / Fulcrum Therapeutics, Inc. 5,000,000
2024-08-26 13G AMLX / Amylyx Pharmaceuticals, Inc. 4,643,812
2024-03-15 13G NKTR / Nektar Therapeutics 20,046,350
2024-02-15 13G MLYS / Mineralys Therapeutics, Inc. 3,185,185
2024-02-15 13G ADVM / Adverum Biotechnologies, Inc. 20,763,572
2024-01-16 13G ATXS / Astria Therapeutics, Inc. 4,368,928
2023-10-16 13G VTGN / Vistagen Therapeutics, Inc. 2,702,157